To determine the risk of pelvic lymph node (LN) metastases at radical prostatectomy (RP) for Gleason score (GS) ≤7: 3 + 3 = 6 (grade group [GG]1); 3 + 4 = 7 (GG2); 3 + 4 = 7 (GG2) with tertiary pattern 5 (T5); 4 + 3 = 7 (GG3); 4 + 3 = 7 (GG3) with T5, using the 2014 modified Gleason grading system and the novel GG system.
Materials and Methods
We searched our RP database to indentify cases of GS ≤7 prostate cancer with simultaneous pelvic LN dissection (PLND) in the period between 2005 and 2014. Since 2005, we have graded all glomeruloid and cribriform cancer as Gleason pattern 4 and have graded mucinous adenocarcinoma based on the underlying architectural pattern, consistent with the 2014 modified Gleason grading system. All RPs were embedded in entirety, including the PLND. A total of 7 442 cases were identified, of which 73 had at least one positive LN (+LN).
Results
The incidence rates for regional LN metastases at RP for 3 + 3 = 6 (GG1), 3 + 4 = 7 (GG2), 3 + 4 = 7 (GG2) with T5, 4 + 3 = 7 (GG3) and 4 + 3 = 7 (GG3) with T5 were 0, 0.6, 0.4, 4.3 and 6.3%, respectively. There was a statistically significant difference in risk of +LNs at RP between the grade groups, as defined by the novel GG system. There was no statistically significant difference in risk of +LNs at RP for men with 3 + 4 (GG2) vs 3 + 4 (GG2) with T5 and for men with 4 + 3 (GG3) vs 4 + 3 (GG3) with T5. Non-pelvic LN involvement was identified in 0.2% of all RP cases. Two patients with GS 3 + 4 = 7 with <5% pattern 4 experienced LN metastases.
Conclusion
This study supports our previous finding that men with GS 6 (GG1) at RP have no risk of LN metastases. These findings also support the 2014 revisions to the Gleason grading system where 3 + 3 with T4 (2005 modified grading system) is now considered 3 + 4 (GG2), with a comment on percent pattern 4, because <5% pattern 4 increases the risk of LN metastases. It also supports keeping 3 + 4 (GG2) with T5 (<5% pattern 5) and 4 + 3 (GG3) with T5 with their respective grade groups, with a notation of T5 because the <5% higher grade component did not increase the risk of LN metastases within a given GG. Our findings highlight that 3 + 4 (GG2) and
Introduction
There have been many changes to the Gleason grading system, most recently after the 2005 and 2014 consensus conferences [1] . With the 2005 modified system, a number of studies have indicated better correlation between biopsy and radical prostatectomy (RP) Gleason score (GS) and stage, as well as with biochemical recurrence, yet there remains significant deficiencies. [2] [3] [4] [5] [6] [7] . In practice, GS 6 is currently the lowest score assigned on a scale for 2-10 which logically, but incorrectly, leads patients to believe they have an intermediate grade tumour. Using the 2005 modified Gleason grading system, we have previously shown, in large single and multi-institutional RP cohorts, that pure GS 6 prostate cancer does not spread to pelvic lymph nodes (LNs) and virtually has no risk of progression when organ-confined with negative margins at RP [8] [9] [10] . Other large series have confirmed low rates of positive LNs (+LNs) in men with GS 6 in the RP specimen; however, these series included RPs that were graded before the International Society of Urological Pathology (ISUP) conference in 2005, when Gleason pattern 3 represented a less homogenous group of cancer [11] [12] [13] [14] [15] [16] . A second issue with the Gleason grading system with respect to our GS ≤7 study group, is that 3 + 4 and 4 + 3 are often lumped together in the literature [17, 18] . The D'Amico and National Comprehensive Cancer Network (NCCN) 2016 prostate cancer risk classification system includes GS 7 within the intermediate-risk category, without recognizing the prognostic distinction between 3 + 4 = 7 and 4 + 3 = 7 [19] .
In 2013, the senior author of the present paper (J.I.E.) reported data from 7 869 patients who underwent RP at the Johns Hopkins Hospital and proposed a novel grading system composed of five grade groups (GGs) based on the significantly modified Gleason system [20] . The different GGs had distinct biochemical recurrence-free survival rates and were predictive of grade at biopsy that was followed by RP or radiation therapy. These findings were validated in a larger 2014 multi-institutional study, which included 20 845 patients [7] . With the post-2005 modifications of the Gleason grading system showing no metastases with pure GS 6 (GG1) prostate cancer at RP, it is not known whether GS 3 + 4 = 7 (GG2) at RP may also be associated with no metastases and, if metastases do occur, how does the rate compare with GS 4 + 3 = 7 (GG3) prostate cancer at RP. The aim of the present study was to better understand the biology of GS 7 cancer in the modern post-2005 era; the results cannot directly be related to needle biopsies, given the potential for upgrading and less likely downgrading with GS 3 + 4 = 7 and both upgrading and downgrading with GS 4 + 3 = 7 on biopsy.
Materials and Methods
The institutional review board-approved Johns Hopkins Database (1982 Database ( -2014 A total of 7 906 GS ≤7 RPs with simultaneous PLND were identified. The vast majority of PLNDs were 'limited/ standard' as previously described [11, 21] . In 2010, pathological examination of anterior fat pad (AFP) tissue became routine at our institution.
All RPs were step-sectioned at 3-5-mm intervals and embedded in entirety, including the PLND and AFP tissue. A GS was assigned to the dominant tumour nodule. All pathology reports were reviewed to determine the presence of LNs in the PLND, total number of sampled LNs and +LNs per case and the distribution of the +LN (i.e. laterality of pelvic LN, AFP and periprostatic LN).
The cohort was split into five grading permutations within GS ≤7: 3 + 3 = 6 (GG1); 3 + 4 = 7 (GG2); 3 + 4 = 7 (GG2) with tertiary pattern 5 (T5); 4 + 3 = 7 (GG3); and 4 + 3 = 7 (GG3) with T5. Cases with ≥95% T4 are considered GS 4 + 4 = 8 in the 2005 and 2014 modified Gleason grading systems and were excluded. The decision not to consider >5% percent pattern 5 in RP specimens as a tertiary component, but to include it as the secondary pattern was agreed to at the ISUSP 2014 consensus conference, but the manuscript concerning tertiary patterns that was planned was never completed. The rationale for this grading rule was: (i) to achieve uniformity amongst pathologists; and (ii) to allow only limited pattern 5 as a 'tertiary' pattern because the goal of noting a tertiary pattern is not just to say it is the third most common pattern but to denote a limited amount of T5 with a prognosis that is not as bad compared with greater amounts of T5; if T5 was defined solely as the third most common pattern, then up to 20% T5 could be considered tertiary, which is a large extent of pattern 5.
Slide re-review was not feasible for our entire study cohort; however, we re-reviewed the RP cases with GS 3 + 4 = 7 with T5 and with +LNs (n = 1) to verify the <5% component of Gleason pattern 5. Cases with GS 3 + 4 = 7 with +LNs (n = 19) were also reviewed. Patient age, clinical stage and preoperative PSA levels were retrieved from the RP database. The patients in our database had not received neoadjuvant therapy before RP.
Statistical analysis was performed with STATA â , (StataCorp LP, College Station, TX, USA). P values were calculated using Student's t-test and the chi-squared test. Statistical significance was considered at P ≤ 0.05.
Results
A total of 7 442 RPs with PLND were identified, of which 73 (1%) had +LNs. Baseline clinicopathological characteristics are shown in Table 1 . The mean (range) patient age was 58.6 (34-81) years. Preoperative PSA levels and clinical stage were unavailable in 96 and 178 cases, respectively. The overall mean PSA level was 5.8 ng/mL. The majority of patients had T1c (79.6%) and the minority had T3 disease (0.2%). Stages T2b, T2c and T3 were combined into a single group for statistical analysis because of the low volume of cases (n = 391). However, Clinical T3 was kept separate for illustration purposes in all the Tables and Figures. The mean number of LNs removed in the RPs with +LNs was 11.7. When +LNs were present, the mean number of +LNs was 1.4 and the mean overall percent was 19.2%. The percent +LNs per side when PLND were involved was 33.6%; bilateral PLND were involved in 5.5% of the RPs (n = 4).
Non-pelvic LN involvement was identified in 16.4% of RPs with +LNs and 0.2% of all RPs (n = 12). Of the latter, seven were periprostatic LNs and five were AFP LNs. Non-pelvic LNs represented the only +LNs in 12.3% of the RPs with +LNs and 0.1% of all RPs (n = 9). Detailed clinicopathological characteristics of the involved non-pelvic LNs are shown in Table 2 .
The incidence of LN metastases at RP for 3 + 3 (GG1), 3+4 (GG2), 3 + 4 (GG2) with T5, 4 + 3 (GG3), and 4 + 3 (GG3) with T5 was 0, 0.6, 0.4, 4.3 and 6.3%, respectively, as illustrated in Figs 1 and 2. There was a statistically significant difference in risk of LN metastases at RP between the GGs; however, there was no statistically significant difference in risk of LN metastases at RP within a given GG when T5 was present (P = 0.17 for GG2; P = 0.19 for GG3). The percentage of +LNs increased with RP GS, PSA levels and clinical T stage. GS, preoperative PSA levels and clinical T stage were independent predictors of LN metastases at RP on both univariate (<0.001 for all three) and multivariable analysis (Table 3) . On re-review of the 19 GS 3 + 4 = 7 (GG2) RPs with +LNs, two cases were identified with <5% pattern 4; in both of these cases the tumour volume was not high, such that the absolute volume of pattern 4 was also limited.
Discussion
In the current Gleason grading era, GS 6 represents a more homogenous tumour population that has a uniformly better prognosis [8] [9] [10] . Between the 2005 and 2014 ISUP Grading Consensus conferences, the scope of Gleason pattern 4 was widened to include all cribriform and glomeruloid glands, and mucinous adenocarcinoma are graded based on the underlying architectural pattern [22] . The latter updates have been in effect at our institution since 2005, although there remained unresolved issues at the 2005 ISUP consensus. In the present study, we found no risk of having +LNs at RP for GS 6 tumours (0% pattern 4), which was consistent with our previous study [10] .
In the present study, we identify the risk of LN metastases at RP of GS ≤7 disease with and without T5 using the 2014 modified Gleason grading system and the novel GG system. Our study cohort was split into five grading permutations accepted for GS ≤7 in the 2014 revisions to the Gleason grading system for statistical analysis: 3 + 3 = 6 (GG1); 3 + 4 = 7 (GG2); 3 + 4 = 7 (GG2) with T5; 4 + 3 = 7 (GG3); and 4 + 3 = 7 (GG3) with T5. GS 3 + 4 (GG2) included cases with >0 to ≤50% pattern 4, while GS 4 + 3 (GG3) included cases with >50 to <95% pattern 4.
We found an increased risk of having +LNs with increasing percent pattern 4 as divided by the GGs (0%; >0 to ≤50%; >50 to <95%). The presence of a small portion (<5%) of
Gleason pattern 4 conferred a risk of having +LNs as seen with two cases in the present study. This finding supports the grouping of such cases with GS 3 + 4 = 7 in the 2014 modified Gleason grading system as opposed to the previous grouping with GS 6 with a notation of T4. Similarly, this supports the classification of such cases as GG2 under the novel GG system.
As we do not use immunohistochemical stains to diagnose cancer on RP specimens; intraductal carcinoma (IDC), a mimicker of cribriform pattern 4 may have accounted for some of the pattern 4 diagnosed on the GS 7 RPs. It is recommended that IDC not be assigned a grade, as there are rare cases with only IDC on RP, which have an excellent prognosis. Some of our cases may have been diagnosed as GS 4 + 3 (GG3), yet might have actually represented GS 3 + 4 with IDC. Kryvenko et al. [23] reported that patients with GS 7 on RP specimens with LN metastases were twice as likely to have IDC than a matched control cohort of patients without LN metastases. There are multiple studies documenting that IDC is associated with more aggressive tumours [24, 25] . Nevertheless, it is not routine practice to perform immunohistochemical stains on RP specimens to identify IDC, and IDC is only noted when identifiable on routine haematoxylin and eosin-stained sections. In general, IDC is We did not find a statistically significant difference in risk of having +LNs within GS 3 + 4 (GG2) and GS 4 + 3 (GG3) when T5 was present (GG2, P = 0.17; GG3, P = 0.19) because of the small number of +LN events in our cohort (n = 73) and the small number of T5 RPs in each GG (GG2, n = 235; GG3, n = 345). In the RP literature, the presence of a higher grade tertiary pattern has been associated with higher pathological stage and biochemical recurrence when compared with the same GS tumour without a tertiary pattern [26] [27] [28] [29] [30] [31] [32] [33] [34] . The presence of a tertiary higher grade component has not been addressed in the novel GG system as the magnitude of its effect is not uniform across each GG [7] . For the time being, until larger multi-institutional studies can be performed, it is prudent to continue recording T5 separately when present. Our findings support keeping GS 3 + 4 with T5 as GG2 and GS 4 + 3 with T5 as GG3, given a similar risk of LN metastases within a given GG.
The present study reflects the risk of LN metastases with standard PLND at RP. The risk might be different with extended PLND as studies have shown that staging accuracy depends on the extent of the anatomical template used, but higher complication rates are more likely [15, [35] [36] [37] [38] . The number or percentage of +LNs seems to be more important for determining outcomes, although increasing LN yield may result in improved survival rates by removing micrometastatic nodal tissue [11, 13, 21, [39] [40] [41] [42] [43] [44] [45] .
In the present study, non-pelvic (periprostatic and AFP) LNs were involved in 16.4% of RPs with N1 disease and 0.2% of all RPs (n = 12). Seven were periprostatic LNs, which are small lymph nodes (mean 1.9 mm) found in 0.8-4.4% of RPs and are predominantly located posteriorly/posterolaterally at the base of the prostate or adjacent to the seminal vesicle [46] [47] [48] [49] . Five were AFP LNs; their identification coincided with the beginning of pathological examination of this tissue at our institution in 2010. All of these RPs with non-pelvic +LNs had a moderate to extensive amount of tumour volume, of which 83% were either GS 4 + 3 or GS 4 + 3 with T5. They were all pT3 stage, with the exception of one pT2 RP, and 50% of patients had preoperative PSA levels ≥10 ng/mL. Both periprostatic and AFP tissue sampling offer the opportunity to improve staging accuracy without increasing the patients' morbidity beyond that which would already exist with the RP procedure. Nine patients in our cohort were upstaged to N1 disease as a result of the identification of an isolated +LN outside of the PLND (five periprostatic and four AFP tissue). Up to 8% (3/37) of +LNs were isolated LN metastasis when periprostatic LNs were present in a wholemounted RP study, and positive periprostatic LNs may be associated with biochemical recurrence, although it is unclear if this is as adverse as pelvic LN metastases [46, 48] . These findings underscore the importance of proper tissue sampling when processing an RP specimen. Adequate periprostatic LN sampling can be achieved by submitting the entire posterior half of the prostate, which has been recommended when the entire RP cannot be submitted [50] . AFP tissue is usually formally mobilized during robot-assisted RPs, to help define the prostate apex and prostate/bladder junction, but is not routinely submitted for pathological assessment [51] . Published series have shown that LNs can be identified in 5.5-16.7% of AFP tissue with a 0.9-2.5% incidence rate of metastases [45, [52] [53] [54] [55] . In the present study, four patients were upstaged to N1 disease as a result of isolated AFP LN metastases. The above findings raise the issue as to whether AFP tissue should be routinely submitted for pathological examination. According to one study the additional cost of AFP tissue examination was approximately $60 [45] . As 92% of the patients with AFP tissue LN involvement in that study had preoperative features consistent with intermediate-or high-risk disease, the authors proposed limiting detailed pathological analysis of AFP tissue to such patients.
In conclusion, this study supports our previous finding that men with GS6 (GG1) at RP have no risk of LN metastases. These findings also support the 2014 revisions to the Gleason grading system where GS6 with T4 (2005 modified grading system) is now considered GS 3 + 4 (GG2) with a comment on percent pattern 4, because a <5% pattern 4 increases the risk of LN metastases. It also supports keeping GS 3 + 4 (GG2) with T5 and 4 + 3 (GG3) with T5 with their respective GGs, with a notation of T5. The <5% higher grade component did not increase the risk of LN metastases within a given GG. Our findings highlight that 3 + 4 (GG2) with and without T5 and 4 + 3 (GG3) with and without T5 are distinct groups with respect to LN metastases and should not be combined under the umbrella designation of GS7 as is often the case in the literature with the Gleason grading system.
